Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy. BMS drug currently only licensed treatment in this setting. ... surveillance, which is usual current management for completely resected stage III and IV melanoma.”.

Latest news

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    Keytruda is first I-O drug cleared for melanoma in China. Company chasing rival BMS in world's biggest market. ... Merck &Co’s immuno-oncology blockbuster Keytruda has become the first drug in its class to be approved in China for advanced melanoma.

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... indicates that the drugs could "transform the standard of care in the melanoma adjuvant setting".

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older. ... led analysts at EvaluatePharma to predict that Merck

  • Opdivo tops Yervoy in adjuvant melanoma trial Opdivo tops Yervoy in adjuvant melanoma trial

    Opdivo tops Yervoy in adjuvant melanoma trial. BMS’nivolumab reduced the recurrence rate of melanoma compared to Yervoy. ... Opdivo (nivolumab) reduced the recurrence rate for patients with high-risk, advanced-stage melanoma who received the drug along

More from news
Approximately 2 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’– ie ... While use of Imlygic has been limited, its

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics